A narrative review of the RTS S AS01 malaria vaccine and its implementation in Africa to reduce the global malaria burden

The RTS, S/AS01 vaccine is a significant milestone in advancing malaria control, especially in Africa, where the heavy burden of this disease is prevalent. The objective of this study is to discuss the effectiveness and utilization of the RTS, S/AS01 vaccine in Africa while simultaneously addressing the gaps and associated issues. We also explore briefly the R21/Matrix-M vaccines recommended by the World Health Organization (WHO) for children aged five months and older. Essential considerations include but are not limited to the vaccine's effectiveness, implementation challenges, available funding sources, public acceptance, and compatibility with various conventional prevention methods for malaria, like insecticide-coated bed nets and antimalarial medicines. This paper also examines the global practices for integrating vaccines into public health systems and policies while emphasizing sustainable and equitable approaches. By drawing from the lessons learned from the implementations of pilot programs as well as early adoption of the RTS, S/AS01 malaria vaccine, this perspective study tries to identify the key factors that may enhance the impact of the vaccine in the fight against malaria and significantly contribute to the vision of complete eradication the disease. Further research needs to be carried out regarding the efficacy and duration of protection of the RTS, S/AS01 vaccine.